{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T17:12:27Z","timestamp":1762017147207},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2007,1,3]],"date-time":"2007-01-03T00:00:00Z","timestamp":1167782400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2007,1,18]]},"DOI":"10.1007\/s00228-006-0239-3","type":"journal-article","created":{"date-parts":[[2007,1,2]],"date-time":"2007-01-02T13:12:13Z","timestamp":1167743533000},"page":"197-203","source":"Crossref","is-referenced-by-count":38,"title":["Evaluation of the prescription and utilization patterns of statins in an Italian local health unit during the period 1994\u20132003"],"prefix":"10.1007","volume":"63","author":[{"given":"Paola","family":"Deambrosis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Saramin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianni","family":"Terrazzani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Scaldaferri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrizia","family":"Debetto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pietro","family":"Giusti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Chinellato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,1,3]]},"reference":[{"key":"239_CR1","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1136\/bmj.321.7267.983","volume":"321","author":"M Pignone","year":"2000","unstructured":"Pignone M, Phillips C, Mulrow C (2000) Use of lipid lowering drugs for primary prevention of coronary artery disease: metanalysis of randomized clinical trials. Br Med J 321:983\u2013986","journal-title":"Br Med J"},{"key":"239_CR2","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1001\/jama.1997.03550040069040","volume":"287","author":"PR Hebert","year":"1997","unstructured":"Hebert PR, Gaziano M, Chan KS, Hennekens CH (1997) Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 287:313\u2013321","journal-title":"JAMA"},{"key":"239_CR3","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1001\/jama.279.18.1458","volume":"279","author":"J Avorn","year":"1998","unstructured":"Avorn J, Monette J, Lacour A, Bohn RL, Monane M, Mogun H, LeLorier J (1998) Persistence of use of lipid-lowering medications: a cross-national study. JAMA 279:1458\u20131462","journal-title":"JAMA"},{"key":"239_CR4","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1046\/j.1365-2125.2000.00192.x","volume":"49","author":"J Larsen","year":"2000","unstructured":"Larsen J, Vaccheri A, Andersen M, Montanaro N, Bergman U (2000) Lack of adherence to lipid lowering drug treatment. A comparison of utilization patterns in defined population in Funen, Denmark, and Bologna, Italy. Br J Clin Pharmacol 49:463\u2013471","journal-title":"Br J Clin Pharmacol"},{"key":"239_CR5","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/j.1365-2125.2005.02478.x","volume":"60","author":"T Walley","year":"2005","unstructured":"Walley T, Folino-Gallo P, Stephens P, Van Ganse E (2005) On behalf of the EuroMedStat group. Trends in prescribing and utilization of statins and other lipid lowering drugs across Europe 1997\u20132003. Br J Clin Pharmacol 60:543\u2013551","journal-title":"Br J Clin Pharmacol"},{"key":"239_CR6","unstructured":"Ministero della Salute (2003) L\u2019uso dei farmaci in Italia: rapporto nazionale anno 2003. Il Pensiero Scientifico Editore, Rome, pp 82\u201386"},{"key":"239_CR7","volume-title":"ATC Index with DDDs","author":"World Health Organization Collaborating Centre for Drug Statistics Methodology","year":"2000","unstructured":"World Health Organization Collaborating Centre for Drug Statistics Methodology (2000) ATC Index with DDDs. WHO, Oslo"},{"key":"239_CR8","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1001\/jama.290.12.1567","volume":"290","author":"M Mitka","year":"2003","unstructured":"Mitka M (2003) Expanding statin use to help more at-risk patients is causing financial heartburn. JAMA 290:2243\u20132245","journal-title":"JAMA"},{"key":"239_CR9","first-page":"921","volume":"169","author":"J Genest","year":"2003","unstructured":"Genest J, Frohlich J, Fodor G, McPherson R, Working Group on Hypercholesterolemia and Other Dyslipidemias (2003) Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. Can Med Assoc J 169:921\u2013924","journal-title":"Can Med Assoc J"},{"key":"239_CR10","first-page":"187","volume":"7","author":"P Ambrosis De","year":"2005","unstructured":"De Ambrosis P, Saramin C, Terrazzani G, Scaldaferri E, Giusti P, Chinellato A (2005) Ten years of statin utilization: adherence to therapy and cost of treatment. Pharmacoeconomics 7:187\u2013194","journal-title":"Pharmacoeconomics"},{"key":"239_CR11","doi-asserted-by":"crossref","unstructured":"Chinellato A, Terrazzani G, Debetto P, Zambon P, Guzzinati S, Walley T, Giusti P (2006) Retrospective analysis of opioid prescriptions in cancer patients in a northern Italian Region. Br J Clin Pharmacol 62:130\u2013133","DOI":"10.1111\/j.1365-2125.2006.02600.x"},{"key":"239_CR12","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1136\/bmj.326.7404.1419","volume":"326","author":"NJ Wald","year":"2003","unstructured":"Wald NJ, Law MR (2003) A strategy to reduce cardiovascular disease by more than 80%. Br Med J 326:1419\u20131422","journal-title":"Br Med J"},{"key":"239_CR13","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","volume":"366","author":"C Baigent","year":"2005","unstructured":"Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R, Cholesterol Treatment Trialists\u2019 (CTT) Collaborators (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366:1267\u20131278","journal-title":"Lancet"},{"key":"239_CR14","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1586\/14779072.2.3.431","volume":"2","author":"P Schwandt","year":"2004","unstructured":"Schwandt P, Brady AJ (2004) Achieving lipid goals in Europe: how large is the treatment gap? Expert Rev Cardiovasc Ther 2:431\u2013439","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"239_CR15","doi-asserted-by":"crossref","first-page":"208","DOI":"10.5694\/j.1326-5377.1996.tb94138.x","volume":"164","author":"LA Simons","year":"1996","unstructured":"Simons LA, Levis G, Simons J (1996) Apparent discontinuation rates in patients prescribed lipid-lowering drugs. Med J Aust 164:208\u2013211","journal-title":"Med J Aust"},{"key":"239_CR16","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1046\/j.1365-2796.1998.00294.x","volume":"243","author":"M Eriksson","year":"1998","unstructured":"Eriksson M, Hadell K, Holme I et al (1998) Adherence with and efficacy of treatment with pravastatin and cholestyramine: a randomized study on lipid lowering in primary care. J Intern Med 243:373\u2013380","journal-title":"J Intern Med"},{"key":"239_CR17","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/j.1365-2125.2005.02355.x","volume":"59","author":"S Perreault","year":"2005","unstructured":"Perreault S, Blais L, Dragomir A, Bouchard MH, Lalonde L, Laurier C, Collin J (2005) Persistence and determinants of statin therapy among middle-aged patients for primary and secondary prevention. Br J Clin Pharmacol 59:564\u2013573","journal-title":"Br J Clin Pharmacol"},{"key":"239_CR18","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1365-2125.2005.02569.x","volume":"61","author":"JG Hugtenburg","year":"2006","unstructured":"Hugtenburg JG, Blom AT, Kisoensingh SU (2006) Initial phase of chronic medication use; patients\u2019 reasons for discontinuation. Br J Clin Pharmacol 61:352\u2013354","journal-title":"Br J Clin Pharmacol"},{"key":"239_CR19","doi-asserted-by":"crossref","first-page":"544","DOI":"10.18553\/jmcp.2003.9.6.544","volume":"9","author":"A Morrison","year":"2003","unstructured":"Morrison A, Glassberg H (2003) Determinants of the cost-effectiveness of statins. J Manag Care Pharm 9:544\u2013551","journal-title":"J Manag Care Pharm"},{"key":"239_CR20","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2165\/00019053-199915030-00002","volume":"15","author":"J Urquhart","year":"1999","unstructured":"Urquhart J (1999) Pharmacoeconomic consequences of variable patient compliance with prescribed drug regimens. Pharmacoeconomics 15:217\u2013228","journal-title":"Pharmacoeconomics"},{"key":"239_CR21","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2165\/00019053-200523010-00002","volume":"23","author":"AM Peterson","year":"2005","unstructured":"Peterson AM, McGhan WF (2005) Pharmacoeconomic impact of non-compliance with statins. Pharmacoeconomics 23:13\u201325","journal-title":"Pharmacoeconomics"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-006-0239-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-006-0239-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-006-0239-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,7]],"date-time":"2021-08-07T05:09:32Z","timestamp":1628312972000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-006-0239-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1,3]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,1,18]]}},"alternative-id":["239"],"URL":"https:\/\/doi.org\/10.1007\/s00228-006-0239-3","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,1,3]]}}}